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The current gold standard for the diagnosis of viable Mycobacte-
rium tuberculosis bacteria is culture [1]. Mycobacterial culture is per-
formed in laboratories worldwide providing absolute confirmation of
the presence of the pathogen. The culture of mycobacteria has several
disadvantages: it requires a high level of technological facilities, and
is relatively costly. In addition, time to detection takes up to 2
months, significantly delaying the diagnosis of active tuberculosis in
a large number of patients. Although less sensitive, smear microscopy
is rapid and widely applied, it is not specific for Mycobacterium tuber-
culosis infection, cannot differentiate between viable and dead bacte-
ria, and is unable to detect drug-resistance. A more rapid assay that
can easily detect viable Mycobacterium tuberculosis bacteria would be
an important advance for clinicians diagnosing and treating patients
with tuberculosis.
During the last decade, molecular tests have revolutionized the
field of TB diagnostics [2]. Molecular identification of mycobacterial
DNA using assays such as the GenXpert MTB/RIF or the line-probe
assays (for example, Hain Life Science, Nehren, Germany) allow the
pathogen’s detection within a few hours [3]. Importantly, these
assays simultaneously identify some resistance markers aiding the
identification of patients being infected with drug-resistant tubercu-
losis. However, the long-lasting stability of DNA does not allow one
to reliably differentiate between viable and dead bacteria [4].
Published recently in EBioMedicine, Wang and colleagues con-
ducted a prospective trial to evaluate a novel culture free assay to
detect viable Mycobacterium tuberculosis bacteria in sputum samples
from Taiwanese tuberculosis patients [5]. By heating the samples to
46 °C, the secretion of a mycobacterial protein (MPT64) is induced.
Only viable Mycobacterium tuberculosis bacteria are able to respond
in this way, hereby allowing the detection of MPT64 by an enzyme-E-mail address: jheyckendorf@fz-borstel.de (J. Heyckendorf).
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MPT64 is not produced by non-tuberculous mycobacteria, it adds to
the assay’s specificity. The overall diagnostic performance against
culture as gold standard was high with a sensitivity of 86.9% and a
specificity of 92.0% corresponding to results from the GenXpert
(Cepheid, Sunnyvale, USA). MPT64 concentrations correlated well
with mycobacterial viability and load as measured by colony forming
units. In a group of treated patients, the specificity, positive and nega-
tive predictive values of smear microscopy or GenXpert Ultra fell
more than the culture free TB test, suggesting that it is selectively
detecting viable organisms opening the possibility of treatment
monitoring.
Several molecular methods for treatment monitoring have been
reported recently. These depend on various measures of Mycobacte-
rium tuberculosis RNA species in sputum samples. These include the
tuberculosis molecular bacterial load assay that detects changing
concentrations of 16SrRNA [6]. Clinical studies will be needed to see
whether this assay described by Wang and colleagues has the capa-
bility of delivering treatment monitoring in a clinical situation[2].
This novel culture-free TB test assay represents an attractive alter-
native to established diagnostics that detect specific molecular tar-
gets (cite Wang et al.). Some open questions remain about the
implementation of this assay, including whether the heating step and
the handling of the sample require specific biosafety considerations,
and how robust and reproducible this is in a real-world setting. In
contrast to the molecular assays, the MPT64 assay does not allow the
detection of drug-resistance, limiting its role as a standalone
diagnostic.
There is a pressing need for new diagnostic tools for tuberculosis
and the novel MPT64 assay may be useful to detect the presence of
viable Mycobacterium tuberculosis bacteria rapidly and obviate the
need for culture in some circumstances. The possibility of therapeutic
monitoring in sequential samples will be of particular interest to
clinicians although further studies will be required. This assay cannot
fully replace culture as drug susceptibility tests will still be required
in the context of drug resistance.Contributors
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